Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entry
AbstractWe consider how patent rights and price regulation affect whether new drugs are marketed in a country, and how quickly. The analysis covers a large sample of 68 countries at all income levels and includes all drug launches over the period 1982-2002. It uses newly compiled information on legal and regulatory policy, and is the first systematic analysis of the determinants of drug launch in poor countries. Price control tends to discourage rapid product entry, while the results for patents are mixed. There is evidence that local capacity to innovate matters and that international pricing externalities may play a role.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by Center for Global Development in its series Working Papers with number 61.
Length: 53 pages
Date of creation: Jun 2005
Date of revision:
Contact details of provider:
Web page: http://www.cgdev.org
patent; drugs; access; market entry; price control;
Find related papers by JEL classification:
- D62 - Microeconomics - - Welfare Economics - - - Externalities
- D4 - Microeconomics - - Market Structure and Pricing
- K2 - Law and Economics - - Regulation and Business Law
- K10 - Law and Economics - - Basic Areas of Law - - - General (Constitutional Law)
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
This paper has been announced in the following NEP Reports:
- NEP-ALL-2006-08-26 (All new papers)
- NEP-COM-2006-08-26 (Industrial Competition)
- NEP-HEA-2006-08-26 (Health Economics)
- NEP-IND-2006-08-26 (Industrial Organization)
- NEP-INO-2006-08-26 (Innovation)
- NEP-MIC-2006-08-26 (Microeconomics)
You can help add them by filling out this form.
CitEc Project, subscribe to its RSS feed for this item.
- repec:hal:wpaper:halshs-00566800 is not listed on IDEAS
- Padmashree Gehl Sampath, 2010. "Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Industry," Working Papers id:3336, eSocialSciences.
- Nebibe Varol & Joan Costa-i-Font & Alistair McGuire, 2011. "Explaining Early Adoption on New Medicines: Regulation, Innovation and Scale," CESifo Working Paper Series 3459, CESifo Group Munich.
- Ghauri, Pervez N. & Rao, P.M., 2009. "Intellectual property, pharmaceutical MNEs and the developing world," Journal of World Business, Elsevier, vol. 44(2), pages 206-215, April.
- Kamal Saggi & Santanu Roy, 2011.
"Equilibrium Parallel Import Policies and International Market Structure,"
Vanderbilt University Department of Economics Working Papers
1113, Vanderbilt University Department of Economics.
- Roy, Santanu & Saggi, Kamal, 2012. "Equilibrium parallel import policies and international market structure," Journal of International Economics, Elsevier, vol. 87(2), pages 262-276.
- Roy, Santanu & Saggi, Kamal, 2011. "Equilibrium parallel import policies and international market structure," Policy Research Working Paper Series 5802, The World Bank.
- Patricia M. Danzon & Andrew J. Epstein, 2008. "Effects of Regulation on Drug Launch and Pricing in Interdependent Markets," NBER Working Papers 14041, National Bureau of Economic Research, Inc.
- Emilio Archila & Gabriel Carrasquilla & Marcela Meléndez & Juan Pablo Uribe, 2006. "Estudio sobre la propiedad intelectual en el sector farmacéutico colombiano," INFORMES DE INVESTIGACIÃN 002622, FEDESARROLLO.
- Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
- Patricia M. Danzon & Eric L. Keuffel, 2013. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484 National Bureau of Economic Research, Inc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (David Roodman) The email address of this maintainer does not seem to be valid anymore. Please ask David Roodman to update the entry or send us the correct address.
If references are entirely missing, you can add them using this form.